Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

LIPO

Lipella Pharmaceuticals Inc

Oct 17 • 04:00PM ET

0.4523

Dollar change -0.0054
Percentage change -1.18	%

Healthcare • Biotechnology • USA • NASD

Peers: VKTX EBS EYPT CARA PTGX SCYX GOSS CPIX UBX HOOK

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.63	Insider Own	35.49%	Shs Outstand	6.05M	Perf Week	12.54%
Market Cap	3.62M	Forward P/E	-	EPS next Y	-0.40	Insider Trans	0.35%	Shs Float	5.16M	Perf Month	15.91%
Income	-4.14M	PEG	-	EPS next Q	-	Inst Own	7.87%	Short Float	3.49%	Perf Quarter	-1.05%
Sales	0.51M	P/S	7.09	EPS this Y	28.57%	Inst Trans	199.26%	Short Ratio	0.04	Perf Half Y	-36.59%
Book/sh	0.22	P/B	2.02	EPS next Y	27.27%	ROA	-146.02%	Short Interest	0.18M	Perf Year	-53.85%
Cash/sh	0.15	P/C	3.04	EPS next 5Y	-	ROE	-171.56%	52W Range	0.32 - 2.71	Perf YTD	-55.66%
Dividend Est.	-	P/FCF	-	EPS past 5Y	-189.86%	ROI	-243.13%	52W High	-83.31%	Beta	0.19
Dividend TTM	-	Quick Ratio	4.33	Sales past 5Y	20.14%	Gross Margin	-	52W Low	39.86%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	4.33	EPS Y/Y TTM	1.68%	Oper. Margin	-839.14%	RSI (14)	53.68	Volatility	16.47% 12.20%
Employees	7	Debt/Eq	0.05	Sales Y/Y TTM	34.99%	Profit Margin	-816.71%	Recom	1.00	Target Price	2.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	53.94%	Payout	-	Rel Volume	0.55	Prev Close	0.46
Sales Surprise	0.00%	EPS Surprise	0.00%	Sales Q/Q	27.89%	Earnings	Aug 28	Avg Volume	4.13M	Price	0.45
SMA20	4.28%	SMA50	4.42%	SMA200	-32.99%	Trades		Volume	2,274,111	Change	-1.18%

Oct-15-24 05:00AM	Lipella Pharmaceuticals Announces U.S. Patent Allowance for Innovative Liposomal Drug Delivery Platform (GlobeNewswire) +5.21%
Oct-09-24 10:47AM	Lipella Pharmaceuticals to Present at 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)
Sep-25-24 08:30AM	PRISM MarketView Features Q&A with Dr. Michael Chancellor: Lipella Pharmaceuticals Advances Innovative Treatments for Hemorrhagic Cystitis During Urology Awareness Month (GlobeNewswire)
Sep-24-24 08:00AM	Lipella Pharmaceuticals Reports Encouraging Early Tolerability Results in Phase 2a Trial of LP-310 for Oral Lichen Planus (GlobeNewswire) +10.32%
Aug-27-24 08:00AM	Lipella Pharmaceuticals to Participate at H.C. Wainwright's 26th Annual Global Investment Conference in New York (GlobeNewswire)
05:00AM	Loading…
Aug-22-24 05:00AM	Lipella Pharmaceuticals Launches Innovative Registry to Advance Oral Lichen Planus Research (GlobeNewswire)
Aug-21-24 05:00AM	Lipella Pharmaceuticals Unveils Advanced Bladder Imaging Technique at ICICJ Conference (GlobeNewswire)
Aug-12-24 06:52AM	Lipella doses first two subjects in Phase IIa oral lichen planus treatment trial (Clinical Trials Arena)
05:00AM	Lipella Pharmaceuticals Doses First Two Patients in Phase 2a Oral Lichen Planus Clinical Trial (GlobeNewswire)
Aug-01-24 04:05PM	Lipella Pharmaceuticals Announces Closing of $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire) -9.05% -5.67%
08:00AM	Lipella Pharmaceuticals Announces $1.28 Million Registered Direct Offering of Common Stock Priced At-the-Market Under Nasdaq Rules (GlobeNewswire)
Jul-29-24 05:00AM	Lipella Pharmaceuticals Initiates Phase 2a Trial for LP-310 in Oral Lichen Planus, Enrolls First Patients (GlobeNewswire) +122.52%
May-31-24 08:00AM	Lipella Pharmaceuticals Announces Completion of Site Initiation Visit for Phase 2a Trial of LP-310 in Oral Lichen Planus (GlobeNewswire)
May-29-24 12:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
08:00AM	Lipella Pharmaceuticals Announces Abstract Publication at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
01:53PM	Loading…
May-24-24 01:53PM	LIPO Stock Earnings: Lipella Pharmaceuticals Reported Results for Q4 2023 (InvestorPlace)
May-21-24 08:00AM	Following Guidance from U.S. Food & Drug Administration in Type-C Meeting Lipella Pharmaceuticals to Advance Lead Product Candidate to Phase 2b (GlobeNewswire)
Apr-17-24 08:00AM	Lipella Pharmaceuticals Expands its Advisory Board to Include Oncology Expertise (GlobeNewswire)
Apr-05-24 08:00AM	Lipella Pharmaceuticals to Publish Abstract Detailing Compelling Preclinical Support for New Product Candidate at ASCO 2024 (GlobeNewswire)
Apr-03-24 08:00AM	Lipella Pharmaceuticals Announces FDA Type C Meeting for LP-10 for Hemorrhagic Cystitis (GlobeNewswire)
Mar-07-24 03:23PM	PRISM MarketView Spotlights Lipella Pharmaceuticals as it Seizes Opportunities in Rare Disease (GlobeNewswire)
Mar-05-24 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-410 for Oral Graft-Versus-Host Disease, Advancing Clinical Pipeline (GlobeNewswire) -21.57%
Feb-20-24 08:00AM	Lipella Pharmaceuticals to Present at PropThink Digital Investor Conference (GlobeNewswire)
Dec-20-23 08:00AM	Lipella Pharmaceuticals Marks Successful First Year with Strategic Progress and Key Milestones Accomplished (GlobeNewswire)
Nov-12-23 08:20PM	Lipella Pharmaceuticals gets ODD for LP-310 to treat GvHD (Pharmaceutical Business Review)
Nov-10-23 08:00AM	FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease (PR Newswire) -8.12%
Oct-25-23 04:05PM	Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire) -24.89% -31.95%
Oct-24-23 08:00AM	Lipella Pharmaceuticals Announces $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules (PR Newswire)
Oct-23-23 08:45AM	Rising Number of Studies to Develop Novel Therapies For Pancreatic Ductal Adenocarcinoma (PDAC) Intensely Increasing (PR Newswire)
08:30AM	Lipella Pharmaceuticals to Present at the Fall Foliage MicroCap Rodeo Conference (ACCESSWIRE)
08:00AM	Loading…
Oct-20-23 08:00AM	Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus (PR Newswire) +29.81%
Sep-21-23 08:30AM	Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology (PR Newswire)
Jun-13-23 08:30AM	Lipella Pharmaceuticals: Addressing Significant Unmet Need for Cancer Survivors, Delivering Long Term Value for Shareholders (NewMediaWire) +6.75%
May-15-23 09:15AM	Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update (PR Newswire)
May-14-23 08:12AM	Lipella Pharmaceuticals First Quarter 2023 Earnings: US$0.19 loss per share (vs US$0.19 loss in 1Q 2022) (Simply Wall St.)
May-01-23 08:30AM	Lipella Pharmaceuticals Delivers Late-Breaking Presentation at the American Urological Association Annual Meeting (PR Newswire) -20.90%
Apr-17-23 08:30AM	Lipella Pharmaceuticals Enters Manufacturing Collaboration Agreement with Cook MyoSite (PR Newswire)
Apr-05-23 08:30AM	Lipella Pharmaceuticals Doses First Patient in Human Study of Innovative Contrast Agent (PR Newswire)
Mar-31-23 08:00AM	Lipella Provides Business Update and Reports 2022 Financial Results (PR Newswire) +5.98%
Mar-16-23 08:30AM	Lipella Pharmaceuticals Successfully Completes Phase 2a Clinical Trial; Announces Late-Breaking Presentation at the Annual Meeting of the American Urological Association (PR Newswire) +36.07%
Mar-01-23 08:00AM	Lipella Pharmaceuticals Announces Creation of Oral Health Scientific Advisory Board (PR Newswire)
Jan-11-23 07:30AM	Lipella Pharmaceuticals Announces Successful Top Line Results of Phase 2A Clinical Trial of LP-10 (PR Newswire) +18.01%
Jan-09-23 08:00AM	Lipella Pharmaceuticals to Present at January 2023 Biotech Showcase in San Francisco (PR Newswire)
Dec-22-22 04:05PM	Lipella Announces Closing of Initial Public Offering for Gross Proceeds of $7 Million (PR Newswire) +12.78% -10.89%

Lipella Pharmaceuticals, Inc. develops and commercializes lipid-based therapies for common bladder syndromes. It offers LP-08 which consists of Sphingomyelin Phospholipid bilayers separated by aqueous compartments, LP-09, a liposomal formulation of Botulinum toxin, and LP-10, a proprietary liposomal formulation of Tacrolimus, a potent immunosuppressant and anti-inflammatory agent. The company was founded by Jonathan Kaufman and Michael Chancellor on February 15, 2005 and is headquartered in Pittsburgh, PA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kaufman Jonathan H	See remarks below.	May 14 '24	Buy	0.76	10,000	7,590	898,849	May 15 04:39 PM
Kaufman Jonathan H	See remarks below.	Mar 18 '24	Buy	0.79	30,000	23,649	863,849	Mar 19 06:21 PM
Kaufman Jonathan H	See remarks below.	Mar 19 '24	Buy	0.87	25,000	21,802	888,849	Mar 19 06:21 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

LIPO

Lipella Pharmaceuticals Inc

Upgrade your FINVIZ experience